JP2014510064A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510064A5
JP2014510064A5 JP2013555631A JP2013555631A JP2014510064A5 JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5 JP 2013555631 A JP2013555631 A JP 2013555631A JP 2013555631 A JP2013555631 A JP 2013555631A JP 2014510064 A5 JP2014510064 A5 JP 2014510064A5
Authority
JP
Japan
Prior art keywords
compound
group
formula
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510064A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026744 external-priority patent/WO2012116362A2/en
Publication of JP2014510064A publication Critical patent/JP2014510064A/ja
Publication of JP2014510064A5 publication Critical patent/JP2014510064A5/ja
Pending legal-status Critical Current

Links

JP2013555631A 2011-02-25 2012-02-27 Nrf2活性剤としてのカルコン誘導体 Pending JP2014510064A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446716P 2011-02-25 2011-02-25
US61/446,716 2011-02-25
US201161500272P 2011-06-23 2011-06-23
US61/500,272 2011-06-23
PCT/US2012/026744 WO2012116362A2 (en) 2011-02-25 2012-02-27 Chalcone derivatives as nrf2 activators

Publications (2)

Publication Number Publication Date
JP2014510064A JP2014510064A (ja) 2014-04-24
JP2014510064A5 true JP2014510064A5 (enExample) 2015-04-16

Family

ID=46721498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555631A Pending JP2014510064A (ja) 2011-02-25 2012-02-27 Nrf2活性剤としてのカルコン誘導体

Country Status (6)

Country Link
US (1) US20140088052A1 (enExample)
EP (1) EP2678305A4 (enExample)
JP (1) JP2014510064A (enExample)
AU (1) AU2012222074A1 (enExample)
CA (1) CA2827990A1 (enExample)
WO (1) WO2012116362A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174436A1 (en) 2011-06-15 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2015187934A1 (en) * 2014-06-06 2015-12-10 Cureveda, Llc Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use
ES2570452B1 (es) * 2014-10-15 2017-04-19 Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
WO2016153432A1 (en) * 2015-03-23 2016-09-29 Nanyang Polytechnic Drugs from substituted phenyl cinnamyl ketones
CA3059192A1 (en) * 2016-05-26 2017-11-30 The Regents Of The University Of California Compounds and methods for hematopoietic regeneration
UY37551A (es) 2016-12-27 2018-07-31 Biogen Ma Inc Activador de nrf2
CN107056707B (zh) * 2017-01-23 2019-08-23 温州医科大学 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用
WO2020041169A2 (en) 2018-08-20 2020-02-27 Janssen Pharmaceutica Nv Inhibitors of keap1-nrf2 protein-protein interaction
WO2020094767A1 (en) * 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
JP2023518027A (ja) * 2020-03-13 2023-04-27 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Gpx4化合物及び組成物、並びにそれを使用する治療方法
CN116916917A (zh) * 2021-01-07 2023-10-20 菲利普莫里斯生产公司 包含新烟草碱的组合物及其用途
US20240335395A1 (en) * 2021-07-15 2024-10-10 Allspim Compositions and methods for preventing and/or treating disease associated with il-23 expression
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
CN115572255A (zh) * 2022-04-29 2023-01-06 无锡捷化医药科技有限公司 一种查尔酮类化合物的制备方法
CN115433073B (zh) * 2022-08-15 2024-04-19 兰州大学 一种卡瓦胡椒素b类似物的制备方法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740105B2 (ja) * 1986-03-14 1995-05-01 清蔵 宮田 非線形光学素子
JPH02178249A (ja) * 1988-12-28 1990-07-11 Mitsubishi Kasei Corp 光学活性ケトンの製造法
US20030065039A1 (en) * 1997-06-26 2003-04-03 Statens Serum Institute Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
WO2000018390A1 (fr) * 1998-09-28 2000-04-06 Hsp Research Institute, Inc. Inducteurs d'expression de proteine de choc thermique
WO2003033662A2 (en) * 2001-10-16 2003-04-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
KR100830541B1 (ko) * 2006-08-11 2008-05-21 충남대학교산학협력단 인터루킨-5 저해효과를 갖는 신규 찰콘계 유도체

Similar Documents

Publication Publication Date Title
JP2014510064A5 (enExample)
JP2004514739A5 (enExample)
HRP20201711T1 (hr) Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida
JP2016510012A5 (enExample)
JP2018199684A5 (enExample)
RU2019100425A (ru) Новая доза и препаративная форма
AR098982A1 (es) Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol
Scichilone et al. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
JP6501774B2 (ja) Maba化合物およびコルチコステロイドを含む組合せ剤
JP2013542940A5 (enExample)
JP2010132695A5 (enExample)
SI2393477T1 (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
JP2015519356A5 (enExample)
FI3500241T3 (fi) Yhdistelmähoito copd:lle
US10258634B2 (en) Ciclesonide for the treatment of airway disease in horses
JP2016510012A (ja) Maba化合物およびコルチコステロイドを含む組合せ剤
JP2020023536A (ja) Copdの治療のためのフォルモテロール及びブデソニドの組み合わせ
JP2016516762A5 (enExample)
RU2015145135A (ru) Лечение воспалительных расстройств
JP2014520874A5 (enExample)
JP2011500731A5 (enExample)
HRP20140818T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
JP2007518817A5 (enExample)
JP2017513866A5 (enExample)
JP2019519572A5 (enExample)